2017 American Transplant Congress
A Phase Ib, Open Label, Single Arm Study to Assess the Safety, Pharmacokinetics, and Impact on Humoral Sensitization of SANGUINATE Infusion in Patients with End-Stage Renal Disease.
1U.Cincinnati, OH; 2Prolong Pharmaceuticals, NJ
Purpose:The endeavor and resources spent to study desensitization haven't been matched by an effort to investigate strategies to prevent sensitization.The purpose of this study was…2017 American Transplant Congress
Optimization of Extended-Release Tacrolimus Dose with Mycophenolate Mofetile Based Immunosuppression in De Novo Kidney Transplant Recipients: 2 Years Outcome.
Purpose: Once-daily tacrolimus extended-release formulation (TACER) has been accepted in kidney transplantation, however its optimal dosing are not well determined. We have validated the institutional…2017 American Transplant Congress
Tacrolimus Appears to Be a Protective Factor for De Novo DSA Formation in Non-Sensitized Kidney Transplant Patients.
Background.Development of de novo donor specific antibodies (dnDSA) concerns about 10% of patients within the first year following kidney transplantation and reach about 20% within…2017 American Transplant Congress
De Novo DSA with T Cell Mediated Rejection (TCMR) Leads to Early Allograft Scarring and Dysfunction.
Detection of de novo DSA is associated with adverse outcomes in kidney transplant recipients (KTRs). The relationship between de novo DSA and subsequent TCMR and…2017 American Transplant Congress
Banff 2013 Classification of Renal Allograft Pathology Is Superior to Banff 2007 in Detecting and Managing Milder and Earlier Cases of Antibody-Mediated Rejection.
The 2013 Banff meeting updated the requirements for the diagnosis of acute/active antibody-mediated rejection (AAMR) in kidney allografts. There has been speculation that the changes…2017 American Transplant Congress
Continuation of Immunosuppression Appears to Protect Against Allosensitization in Patients Listed for a Second Kidney Transplant.
Purpose: The current standard of practice after allograft loss is to discontinue immunosuppression (IS) to decrease complications related to prolonged exposure. There is a paucity…2017 American Transplant Congress
Pro Inflammatory Transitional B (TrB) Cells Characterize Renal Allograft Recipients with DSA and T Cell Mediated Rejection (TCMR).
De novo DSA detected post-renal transplantation is associated with adverse outcomes. We have shown that de novo DSA is strongly associated with TCMR. In this…2017 American Transplant Congress
Dual Targeting with Carfilzomib and Tocilizumab Abrogates Antibody-Mediated Rejection and Prolongs Survival in a Highly Sensitized Rhesus Model of Kidney Transplantation.
Duke University Medical Center, Durham, NC; Cedars-Sinai Medical Center, Los Angeles, CA
Purpose:Sensitized recipients have poor access to kidney transplantation (KT) and worse outcomes when transplanted. We have shown that bortezomib inhibits plasma cells (PCs), but does…2017 American Transplant Congress
TFR:TFH Cell Ratio Correlates with Anti-Donor Germinal Center Reactivity and Donor-Specific Antibody Formation Following Transplantation.
Emory Transplant Center, Emory University School of Medicine, Atlanta, GA
Kidney transplantation is the treatment of choice for patients with end-stage renal disease. Although short-term outcomes are excellent, long-term allograft survival rates remain inadequate. It…2017 American Transplant Congress
The Impact of Belatacept on Anti-HLA Antibodies of Highly Sensitized Kidney Transplant Recipients.
Emory Transplant Center, Atlanta, GA
Background: Anti-HLA antibodies often prevent successful organ transplantation. Interestingly, belatacept limits de novo antibody production within the germinal center, but its impact on long-lived plasma…
- « Previous Page
- 1
- …
- 23
- 24
- 25
- 26
- 27
- …
- 40
- Next Page »